(RTTNews) - ADS-TEC Energy PLC (ADSE), a German battery storage and ultra-fast charging solutions provider, on Thursday reported a wider net loss in the first half of fiscal 2026, while operating loss narrowed on expense control, amid weak revenues.
(RTTNews) - Zealand Pharma A/S (ZEAL.CO) said Thursday that Boehringer Ingelheim's investigational Survodutide met its co-primary endpoints in the Phase 3 SYNCHRONIZE-2 trial in adults with obesity or overweight and type 2 diabetes.
(RTTNews) - Kia Corporation (000270.KS), a South Korean automobiles manufacturer, Thursday said that its American subsidiary, reported higher September vehicle sales compared to the same period last year.
(RTTNews) - Genentech, a member of the Roche Group (RHHBY), announced that detailed Phase 3 evERA study results published in the New England Journal of Medicine showed that giredestrant combined with everolimus significantly improved progression-free survival in patients with ER-
(RTTNews) - H. Lundbeck A/S (HLBBF), a biopharmaceutical company, announced positive results from the Phase IV THRIVE trial evaluating eptinezumab in adults with migraine who had an inadequate response to one prior calcitonin gene-related peptide (CGRP)-targeting preventive thera
(RTTNews) - Novacyt S.A. (NCYT.L), a diagnostics company providing molecular testing technologies and services, reported higher revenue and a narrower loss for the six months ended June 30, 2026.
(RTTNews) - Shares of Bassett Furniture Inc. (BSET) gained around 10 percent in the after-market activity on the Nasdaq after the company reported higher profit in the third quarter of fiscal 2026, supported by increased revenue, expense control and tariff refunds.
(RTTNews) - Pfizer Inc. (PFE) reported Thursday that its ongoing Phase 2 study of investigational Tilrekimig met its primary endpoint in adults with moderate to severe atopic dermatitis.
(RTTNews) - H. Lundbeck A/S (HLBBF) announced headline results from the Phase IV THRIVE trial evaluating eptinezumab, an investigational humanised monoclonal antibody administered intravenously, in adults with migraine who had an inadequate response to one prior CGRP-targeting pr
(RTTNews) - Roche (RHHBY) announced new data from the VOYAGER study showing that Vabysmo (faricimab) continued to demonstrate effectiveness, durability and safety in real-world clinical practice across several major retinal diseases.